The agrin/muscle-specific kinase pathway: new targets for autoimmune and 
genetic disorders at the neuromuscular junction

Liyanage, Y; Hoch, W; Beeson, D; Vincent, A

doi:10.1002/mus.1218

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Journal Article

The agrin/muscle-specific kinase pathway: new targets for autoimmune and genetic disorders at the neuromuscular junction

MPS-Authors

/persons/resource/persons282991

Hoch, W
Department Biochemistry, Max Planck Institute for Developmental Biology, Max Planck Society;

External Resource

No external resources are shared

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

There are no public fulltexts stored in PuRe

Supplementary Material (public)

There is no public supplementary material available

Citation

Liyanage, Y., Hoch, W., Beeson, D., & Vincent, A. (2002). The agrin/muscle-specific kinase pathway: new targets for autoimmune and genetic disorders at the neuromuscular junction. Muscle & Nerve, 25(1), 4-16. doi:10.1002/mus.1218.

Cite as: https://hdl.handle.net/21.11116/0000-000D-D873-E

Abstract

The increasing understanding of the structural complexity of the neuromuscular junction (NMJ), and the processes that are important in its development, suggests many possible new disease targets. Here, we summarize briefly the genetic and autoimmune disorders that affect neuromuscular transmission, and the identified targets, including new evidence that antibodies to muscle-specific receptor tyrosine kinase (MuSK) are involved in the pathogenesis of acetylcholine receptor (AChR) antibody-negative myasthenia gravis. We then review the development of the NMJ, focusing on the important roles of nerve-derived agrin and MuSK in clustering of AChRs and other essential components of the NMJ.